Lundbeck and Solvay put promising schizophrenia drug into Phase III trials  

Lundbeck and Solvay Pharmaceuticals announce their joint decision to move bifeprunox into Phase III trials

Danish pharmaceutical firm Lundbeck and Solvay Pharmaceuticals have announced that their candidate schizophrenia drug bifeprunox is to be put into Phase III clinical trials following successful completion of the joint Phase II programme. Bifeprunox, a product of Solvay Pharmaceuticals' drug discovery efforts, belongs to the so-called "atypical" class of antipsychotic drugs, which are reputed to have significantly fewer of the troublesome side effect problems associated with the widely used, less expensive conventional treatments for schizophrenia. Schizophrenia is a severely disabling and chronic form of psychosis that develops in approximately 1% of the population.


If bifeprunox reaches the market, Solvay will have the marketing rights in the US, Canada, Mexico and Japan, while Lundbeck will have the marketing rights for Europe and the rest of the world. Lundbeck and Solvay will jointly market the product in Brazil and Argentina.


Lundbeck A/S markets drugs for the treatment of psychiatric and neurological disorders, and is internationally known for its antidepressant drugs Cipramil and Cipralex (Celexa and Lexapro in US). In 2002, the company's turnover was DKK 9.5 billion (USD 1.4 billion). Solvay Pharmaceuticals is a member of the Solvay Group with sales and marketing companies in more than 45 countries. Its R&D activities are focused on psychiatry, gastroenterology, cardiology and gynaecology. The news is reported on Lundbeck's website.


Link > Lundbeck

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×